Other Solid Cancers Gene-Edited Cell Lines for Drug Discovery

Other solid cancers encompass a diverse group of malignancies not classified among the most common types (e.g., lung, breast, colorectal). According to the World Health Organization (WHO) GLOBOCAN 2020, these cancers collectively account for approximately 3.5 million new cases and 2.2 million deaths annually worldwide. Key risk factors include genetic predisposition, environmental exposures (e.g., asbestos for mesothelioma), chronic inflammation (e.g., hepatitis B/C for hepatocellular carcinoma), and lifestyle factors (e.g., smoking for head and neck cancers). The 5-year survival rate varies widely by cancer type and stage, ranging from >90% for localized thyroid cancer to <20% for metastatic pancreatic cancer, as reported by the National Cancer Institute (NCI) SEER program.

Other solid cancers are ideal for mechanistic studies due to their distinct molecular subtypes, well-characterized public datasets (e.g., TCGA, COSMIC), and unresolved questions regarding tumor heterogeneity, metastasis, and therapy resistance. For example, head and neck squamous cell carcinoma (HNSCC) exhibits high mutational burden and HPV-related subtypes, while hepatocellular carcinoma (HCC) offers a model for inflammation-driven carcinogenesis. Gene-edited cell models enable precise dissection of these pathways.

The pathogenesis of other solid cancers involves several key pathways:

1. p53 Pathway: Inactivation of TP53 via mutation or deletion is common, leading to genomic instability and evasion of apoptosis.

2. Wnt/beta-catenin Pathway: Activating mutations in CTNNB1 or loss of APC drive uncontrolled cell proliferation, especially in hepatocellular carcinoma.

3. PI3K/AKT/mTOR Pathway: Mutations in PIK3CA or PTEN loss activate survival signaling, promoting cell growth and metabolism.

4. MAPK/ERK Pathway: KRAS, NRAS, or BRAF mutations drive constitutive proliferation, frequently observed in pancreatic and biliary tract cancers.

Data from TCGA Pan-Cancer Atlas and COSMIC v98.

Deregulated signaling networks in other solid cancers include:

• • Wnt/beta-catenin: Key nodes: CTNNB1, APC, AXIN1, TCF7L2. Mutations lead to nuclear beta-catenin accumulation and transcription of MYC, CCND1.
• • MAPK/ERK: Key nodes: KRAS, NRAS, BRAF, MEK1/2, ERK1/2. Constitutive activation drives proliferation and survival.
• • PI3K/AKT/mTOR: Key nodes: PIK3CA, PTEN, AKT1, mTOR. Loss of PTEN or activating PIK3CA mutations promote growth and metabolism.
• • p53/ATM: Key nodes: TP53, ATM, CHEK2. Defects impair DNA damage response and apoptosis.

Organoids derived from patient tumors retain 3D architecture and heterogeneity, offering advantages for drug response testing and personalized medicine.

Animal models for other solid cancers include:

• • Patient-derived xenografts (PDX): Implantation of human tumor fragments into immunodeficient mice, preserving tumor heterogeneity and stroma.
• • Genetically engineered mouse models (GEMM): Conditional knock-in of KRAS G12D with TP53 deletion in pancreatic cancer (KPC model).
• • Induced models: Chemical carcinogenesis (e.g., diethylnitrosamine for HCC) or viral oncogene expression (e.g., HBV transgenic mice).

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications, such as TP53 knockout, KRAS G12D knock-in, or CTNNB1 S45Y knock-in. These models allow direct comparison of mutant vs. wild-type cells in an identical genetic background, eliminating confounding factors. Commercially available, sequence-verified gene-edited cell lines accelerate research by providing ready-to-use tools for functional studies, drug screening, and target validation. For example, HCT116 TP53-/- cells are widely used to study p53 loss-of-function effects on chemoresistance.

Knockout and knock-in lines validate the role of specific genes in tumorigenesis. For instance, KRAS G12D knock-in in pancreatic cell lines demonstrates increased proliferation and invasion. TP53 knockout in HCT116 cells confirms its role in apoptosis and cell cycle arrest. These models are essential for establishing causal relationships between mutations and phenotypes.

Isogenic pairs (e.g., wild-type vs. KRAS G12D) enable identification of mutant-specific drug sensitivities. Resistance modeling involves chronic drug exposure to select for resistant clones, which can be analyzed for secondary mutations. For example, MEK inhibitor resistance in KRAS-mutant cells can be traced to acquired mutations in MAP2K1.

CRISPR synthetic lethality screens identify genes that become essential in the context of a specific mutation. For example, in KRAS-mutant cells, knockout of STK33 or TBK1 induces cell death, revealing potential therapeutic targets. These screens leverage genome-wide knockout libraries in isogenic backgrounds.